GFAP and Alzheimer disease: We aimed to examine whether plasma biomarkers of AD (Aβ42/40 and p-tau181), astrocyte-expressed proteins (GFAP) and neurodegeneration (NfL) would differentiate MCI-LB from healthy controls, and MCI-AD from MCI-LB.